Melanoma (C43-C44)



The objectives of this modelling is manifold, as seen from the number of and representatives in respective BPMN lanes. Our perspective is global from content point of view, but leans to some extent on an European perspective with respect to stakeholders and parity with objectives in EU framework programmes.

Process modelling for neoplasms has been initiated with modelling for the NEOPLASMS - Melanoma (C43-C44), and using the Microsoft's Visio 2010 implementation of BPMN.

At this point we aim at ontology and ICT based transparency and coherence. Indeed, we want to demonstrate that various parts must not and cannot be detached, so that e.g. database management issues are detached from the process, in turn detached from quality assurance aspects. Also, the citizen, as target for care, must be in focus and also well specified so that disease and intervention progressions and effects appear as measurable and related results as presentable.

Modelling is at this point and for these demonstrator purposes not intended to be sound and complete, neither from medical, nor from governmental and authority point of view. We have aimed at using a evidence-based approach, and we lean on some particular guidelines and recommendations found from sites representing national and regional authorities and/or professional associations. Doing so, for melanoma we made use e.g. of the Scottish Intercollegiate Guidelines Network (SIGN) guideline for cutaneous melanoma which contains a process description that can be compared to our BPMN based description. Further, the AJCC Cancer Staging Manual is very 'information intensive' so this hs been helpful in particular for the logic counterpart of melanoma.

Process modelling of melanoma in this initial version indeed is far from complete. Viewers may identify missing tasks and flows, or flows not going in expected directions, so the viewer is adviced indeed not to look at the model from completeness point of view, but rather to see it as a starting point where the aim is to embrace process, logic and database management in a common and interconnected framework.

Developments will continue.

Note e.g. how an exemplification of breast cancer could be similarly built upon European guidelines for quality assurance in breast cancer screening and diagnosis. Ultimately, and for cancer, finding commonality in these respective models is also desirable, so that a template process model can be achieved. Our approach is therefore clearly bottom-up, as compared to top-down approach as typically appearing in national authority approaches.

Stakeholder roles involving assessment and quality assurance will also be refined.